Feline leukaemia virus: a review of immunity and vaccination

The availability feline leukaemia virus (FeLV) vaccines has added a new and important dimension to the control of this infectious agent. FeLV vaccination is a controversial issue, however, partly because of differences in the formulation between the current products, partly because of conflicting claims by vaccine manufactures and partly because experimental trials have shown that none of the vaccines provides 100 per cent protection against infection. This paper reviews the role of the immune response in determining the outcome following exposure to FeLV and describes the importance of FeLV subgroups. The five commercial FeLV vaccines currently available in the USA and Europe are described and the published literature on efficacy studies is summarised. However, these efficacy studies are often difficult to interpret for various reasons, including the small numbers of animals used; differences in challenge methods, vaccine strains and vaccine dose employed; and differences in postchallenge monitoring protocols.